Disease flare after treatment discontinuation in a patient with EML4-ALK lung cancer and acquired resistance to crizotinib

J Thorac Oncol. 2012 Aug;7(8):e1-2. doi: 10.1097/JTO.0b013e318257fc1d.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Abdominal Neoplasms / chemically induced*
  • Abdominal Neoplasms / radiotherapy
  • Aftercare
  • Brain Neoplasms / chemically induced*
  • Brain Neoplasms / radiotherapy
  • Crizotinib
  • Drug Resistance, Neoplasm*
  • Female
  • Humans
  • In Situ Hybridization, Fluorescence
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Middle Aged
  • Oncogene Proteins, Fusion / genetics*
  • Protein Kinase Inhibitors / adverse effects*
  • Pyrazoles / adverse effects*
  • Pyridines / adverse effects*

Substances

  • EML4-ALK fusion protein, human
  • Oncogene Proteins, Fusion
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • Crizotinib